North Growth Management Ltd. Cuts Stake in Integer Holdings Co. (NYSE:ITGR)

North Growth Management Ltd. cut its holdings in Integer Holdings Co. (NYSE:ITGR - Free Report) by 2.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 97,000 shares of the medical equipment provider's stock after selling 2,000 shares during the quarter. Integer accounts for 2.5% of North Growth Management Ltd.'s portfolio, making the stock its 14th biggest holding. North Growth Management Ltd. owned 0.29% of Integer worth $12,876,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Creative Planning boosted its stake in Integer by 17.1% in the 2nd quarter. Creative Planning now owns 7,427 shares of the medical equipment provider's stock worth $860,000 after buying an additional 1,085 shares during the last quarter. SG Americas Securities LLC purchased a new position in Integer in the 3rd quarter valued at about $651,000. Handelsbanken Fonder AB grew its stake in Integer by 27.7% during the 3rd quarter. Handelsbanken Fonder AB now owns 10,137 shares of the medical equipment provider's stock valued at $1,318,000 after purchasing an additional 2,200 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Integer by 74.1% in the third quarter. GAMMA Investing LLC now owns 653 shares of the medical equipment provider's stock worth $85,000 after buying an additional 278 shares during the last quarter. Finally, Contravisory Investment Management Inc. raised its stake in shares of Integer by 55.9% in the 3rd quarter. Contravisory Investment Management Inc. now owns 223 shares of the medical equipment provider's stock valued at $29,000 after purchasing an additional 80 shares in the last quarter. 99.29% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ITGR has been the topic of a number of research reports. Truist Financial increased their price target on Integer from $147.00 to $163.00 and gave the stock a "buy" rating in a research report on Wednesday, December 11th. Citigroup upped their target price on Integer from $130.00 to $145.00 and gave the stock a "neutral" rating in a research report on Wednesday, December 11th. Benchmark lifted their price objective on shares of Integer from $130.00 to $140.00 and gave the stock a "buy" rating in a research note on Monday, October 21st. Wells Fargo & Company reiterated an "overweight" rating and issued a $160.00 price target on shares of Integer in a research report on Tuesday, December 3rd. Finally, Piper Sandler reissued an "overweight" rating and set a $140.00 target price (up from $125.00) on shares of Integer in a research note on Friday, October 25th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $146.56.

Integer Stock Down 1.0 %

Shares of ITGR stock traded down $1.40 during trading on Wednesday, reaching $137.30. The company's stock had a trading volume of 226,116 shares, compared to its average volume of 211,954. The business has a fifty day moving average price of $137.89 and a 200-day moving average price of $131.42. Integer Holdings Co. has a one year low of $94.56 and a one year high of $146.36. The company has a quick ratio of 2.09, a current ratio of 3.28 and a debt-to-equity ratio of 0.67. The company has a market cap of $4.61 billion, a price-to-earnings ratio of 42.38, a price-to-earnings-growth ratio of 1.79 and a beta of 1.13.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.